Value Creation Story

At a Glance

ASKA Pharmaceutical—a Focus on Women’s Healthcare

ASKA Pharmaceutical Holdings’ business operations include a pharmaceuticals business, an animal
health business, and a testing business. Rather than focusing solely on promoting each businessindividually, we are using alignment between businesses to drive synergy that will maximize revenue.
Here we highlight our initiatives in female healthcare, a key focus area in the pharmaceutical business,
which accounts for approximately 90% of the Group’s net sales.

60,461 million

No. 1 domestic market share*In the second half of FY2022, we achieved thehighest sales in the Ob/Gyn field in Japan. We
are promoting a variety of initiatives in addition
to pharmaceuticals, including disseminating
information on women’s health.

Pharmaceutical Business: Main Target Diseases
Internal Medicine* Company estimates(Gastroenterology and Thyroid)∙ Hepatic encephalopathy∙ Hyperthyroidism∙ Hypothyroidism∙ Uterine fibroids∙ Endometriosis∙ Dysmenorrhea∙ Menstrual disorders∙ Contraception∙ Emergency
contraception

Livestock and Fisheries∙ Pharmaceuticals for∙ Antibacterial∙ Gastrointestinal∙ Antiparasitic∙ Pharmaceuticals∙ F eed additives∙ Mixed feed
∙ Feed materials

affecting metabolism∙ Antibiotics

pharmaceuticals
pharmaceuticals

Companion Animals∙ Cardiovascular pharmaceuticals∙ Pharmaceuticals affecting metabolism∙ Antiparasitic pharmaceuticals∙ Topical pharmaceuticals∙ Dietary supplements∙ Skincare
Animal Health Business: Main Products
8ASKA HD REPORT 2023

Since our founding in 1920, we have usedhormonal research to address female healthcare.
We will continue creating a wide variety of drugs
in line with the needs of the times so that we cancontinue contributing to women’s health.
See pages 6-7 for details.

See page 24 for details.

∙ Benign prostatic hyperplasia∙ Prostate cancer

pharmaceuticals

100 years

Obstetrics and Gynecology (Ob/Gyn)

Urologybreeding

Female Healthcare Research

Leading company

Net sales in FY2022¥

Ob/Gyn∙ Infertility∙ Imminent miscarriage/
premature birth∙ Labor induction∙ Menopause∙ Iron deficiency anemia∙ STD/Infection

Share of Thyroid Products Market

95%

R&D Expenses

4.2 billion¥The continuous development of our businessdraws on our 100 years of experience andexpertise in the thyroid area. We will strive toensure quality and stable supply, continuing tocontribute to society as a leading company in thethyroid area.

We are a pharmaceutical manufacturer thatdevelops new drugs with a focus on the threepriority areas of internal medicine, Ob/Gyn, andurology. We will work with companies in Japan andabroad, accelerating open innovation to provide
innovative new drugs.

See page 27 for details.

See pages 40-41 for details.

Microdetermination ofEndogenous Hormones∙ H igh sensitivity measurement using LC-MS/MS(Optimization of measurement conditions, separation
and refinement techniques, derivatization)

 ulti-item simultaneous steroid hormone∙Mmeasurement∙ Ultra-high-sensitive estrogen measurement

Measurements Using Non-Invasive
Samples (Hair, nails, etc.)∙ Hair hormone level measurement kit–DHT(androgenetic alopecia)∙ Hair hormone level measurement kit–testosterone(male menopausal disorder)∙ Hair stress hormone level testing and diagnostics
kit–cortisol∙ Nail stress hormone level testing and diagnostics
kit–cortisol

Uterine Fibroids and Endometriosis
Agents (FY2023 Net Sales Forecast)10.0 billion¥Diversity & Inclusion

20.8%

Percentage of Female Manager Candidates

RELUMINA, a uterine fibroids and endometriosis
agent, is a growth driver. In the fifth year since its
launch in 2019, it is expected to reach annual salesof ¥10.0 billion. We expect it to meet its mediumterm management plan target ahead of schedule.

We believe that achieving sustainable growth andenhancing corporate value depend on respecting
diverse values. We aim to create a workplaceenvironment in which all employees, regardless ofage or attributes, can play an active role.

See page 27 for details.

See page 36 for details.

Testing Business: Main Services and Products

ASKA HD REPORT 2023

9